Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 DividendBusiness Wire • 02/01/22
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire • 02/01/22
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release SyndromeBusiness Wire • 01/31/22
FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer SettingsBenzinga • 01/26/22
Vizient Pharmacy Market Outlook: Increased Use of Remdesivir for COVID Pushes it to Top Spot in Total Vizient Member SpendBusiness Wire • 01/26/22
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With AzacitidineBusiness Wire • 01/25/22
Gilead Sciences (GILD) Gains But Lags Market: What You Should KnowZacks Investment Research • 01/25/22
Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID PatientsZacks Investment Research • 01/24/22
FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease ProgressionBenzinga • 01/24/22
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease ProgressionBusiness Wire • 01/21/22